CORD-19:c654596857bce9cdd64ffc51842048643107348c / 480819-481020
Annnotations
CORD-19-Sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T4109 | 0-71 | Sentence | denotes | University of Bonn, Pharmaceutical Microbiology, Bonn, Germany Purpose: |
TextSentencer_T4110 | 72-201 | Sentence | denotes | The intravenous form (IV) of 400 mg Moxifloxacin (MOX), one of the newer fluoroquinolones, has been recently approved by the FDA. |
T30282 | 0-71 | Sentence | denotes | University of Bonn, Pharmaceutical Microbiology, Bonn, Germany Purpose: |
T32271 | 72-201 | Sentence | denotes | The intravenous form (IV) of 400 mg Moxifloxacin (MOX), one of the newer fluoroquinolones, has been recently approved by the FDA. |
Epistemic_Statements
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T610 | 0-201 | Epistemic_statement | denotes | University of Bonn, Pharmaceutical Microbiology, Bonn, Germany Purpose: The intravenous form (IV) of 400 mg Moxifloxacin (MOX), one of the newer fluoroquinolones, has been recently approved by the FDA. |
CORD-19_Custom_license_subset
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T281 | 0-71 | Sentence | denotes | University of Bonn, Pharmaceutical Microbiology, Bonn, Germany Purpose: |
T282 | 72-201 | Sentence | denotes | The intravenous form (IV) of 400 mg Moxifloxacin (MOX), one of the newer fluoroquinolones, has been recently approved by the FDA. |